Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.050
-0.020 (-1.87%)
Nov 20, 2026, 4:00 PM EST - Market closed
Actinium Pharmaceuticals Employees
Actinium Pharmaceuticals had 27 employees as of June 30, 2026. The number of employees did not change compared to the same quarter last year. That makes Actinium Pharmaceuticals the 37,381st largest employer in the world and 5,225th in the United States.
Employees
27
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,296,296
Profits / Employee
$392,444
Market Cap
33.01M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 27 | 0 | - |
| Mar 31, 2026 | 25 | -6 | -19.35% |
| Dec 31, 2025 | 25 | -12 | -32.43% |
| Sep 30, 2025 | 25 | -12 | -32.43% |
| Jun 30, 2025 | 27 | -10 | -27.03% |
| Mar 31, 2025 | 31 | -18 | -36.73% |
| Dec 31, 2024 | 37 | -12 | -24.49% |
| Sep 30, 2024 | 37 | -12 | -24.49% |
| Dec 31, 2023 | 49 | 0 | - |
| Dec 31, 2022 | 49 | 17 | 53.13% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caribou Biosciences | 97 |
| NextCure | 40 |
| eXoZymes | 32 |
| Cue Biopharma | 29 |
| Veru Inc. | 20 |
| Apollomics | 14 |
| Rein Therapeutics | 10 |
| Hyperion DeFi | 9 |
ATNM News
- 5 days ago - Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress - PRNewsWire
- 6 days ago - Actinium Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 6 days ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 10 days ago - Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy - PRNewsWire
- 10 days ago - Actinium begins enrollment for Radianz clinical trial - TheFly
- 11 days ago - Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy - PRNewsWire
- 12 days ago - Actinium forms Scientific Advisory Board - TheFly
- 13 days ago - Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development - PRNewsWire